

Anti-BCMA & CD3 Reference Antibody (Elranatamab)

Catalog # APR11562

Product Information


Application	Functional assay, Kinetics (SPR), Kinetics (BLI), FACS, E, FTA
Primary Accession	Q02223 & P07766
Reactivity	Human
Clonality	Bispecific
Isotype	IgG-like

Additional Information


Target/Specificity	TNFRSF17 / BCMA / CD269,CD3
Expression system	CHO

Protein Information

Images




Anti-BCMA & CD3 Reference Antibody (Elranatamab) on SDS-PAGE under reducing (R) condition. The purity of the protein is greater than 95%.




The purity of Anti-BCMA & CD3 Reference Antibody (Elranatamab) is 99.34%, determined by SEC-HPLC.


Elranatamab-Bcmm bound to BCMA protein, and then rebounded to secondary antibodies (Anti-human-IgG-Fc-HRP), and read OD450. As shown in fig, Elranatamab-Bcmm bound to huBCMA-ECD-His, and the EC50 was 0.055 nM.




Elranatamab-Bcmm bound to huBCMA-HEK293 cells, and then rebounded to fluorescent secondary antibodies (Anti-human IgG, Fcy PE) , and test by flow cytometry. As shown in fig, Elranatamab-Bcmm bound to huBCMA-HEK293 cells, and the EC50 was 1.263 nM.




Elranatamab-Bcmm bound to huCD3e-jurkat cells, and then rebounded to fluorescent secondary antibodies (Anti-human IgG, Fcy PE) , and test by flow cytometry. As shown in fig, Elranatamab-Bcmm bound to huCD3e-jurkat cells, and the EC50 was 64.990 nM.



Co-incubation of Elranatamab-Bcmm with Jurkat cells, then with the addition of huBCMA-HEK293 cells for 6 hours. Bright-Lite was used to detect the fluorescent signal. As shown in fig, Elranatamab-Bcmm was able to activate the NF-AT signaling pathway, and the EC50 was 0.081 nM.



The detected molecular weight of Anti-BCMA & CD3 Reference Antibody (Elranatamab) is 145.21 kDa. The mass spectrum exhibits two peaks, suggesting the possible presence of a homodimer.



Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.